olivLaw · US equity research
Jin Medical International Ltd. ZJYL
Orthopedic, Prosthetic & Surgical Appliances & Supplies · SIC 3842 · Vertical: Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842)
Jin Medical International Ltd. designs and manufactures wheelchairs and living aids for people with disabilities, the elderly and patients in recovery, through the variable interest entity Changzhou Zhongjin in China. The company reported revenue of 20.7 million USD in fiscal 2025, and its legal structure and the 2026 share class reclassification are of interest to investors.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, Jin Medical International Ltd. (ZJYL) stock was 3.09 USD (+13.60% on the day), with market capitalisation 483.7 m USD, P/E 309.0 on diluted EPS of 0.01 USD over the last 12 months, beta 0.70, 52-week range 1.81–5.58 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 72.8
- overbought (≥ 70)
- Bollinger (20, 2)
- 1.59 – 2.71
- above the upper band · %B 1.34 · band width 51.8%
- SMA 50 / 200
- 2.13 / 2.35
- mixed trend
- MACD (12, 26, 9)
- 0.12 / 0.01
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +56.1% | −1.1% | +57.2 pp | — |
| 3 months | +39.8% | −0.5% | +40.3 pp | — |
| 6 months | +34.3% | +4.4% | +30.0 pp | — |
| Year to date | −29.8% | +12.3% | −42.1 pp | — |
| 1 year | −34.3% | +13.5% | −47.8 pp | +2.0% |
| 3 years | −66.5% | +76.4% | −142.9 pp | −0.2% |
| 5 years | unavailable | +63.7% | unavailable | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 0 percentile of its own 3-quarter history (min 1,130.0, median 1,170.0, max 2,690.0; quarters with earnings only).
Fiscal years
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 20.8 m | 19.2 m | 19.8 m | 23.5 m | 20.7 m |
| Revenue YoY | unavailable | −7.6% | +3.3% | +18.6% | −12.0% |
| Net income | 2.6 m | 2.7 m | 2.9 m | 3.7 m | 1.2 m |
| Net income YoY | unavailable | +2.8% | +6.3% | +27.7% | −67.6% |
| Diluted EPS | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 |
| Diluted EPS YoY | unavailable | 0.0% | 0.0% | 0.0% | −50.0% |
| net % | 12.7% | 14.1% | 14.5% | 15.6% | 5.8% |
| Free cash flow | 5.8 m | 1.5 m | 3.0 m | -1.4 m | -3.7 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 30 Sept 2025
- Cash
- 7.5 m USD
- Financial debt
- 18.8 m USD
- Net debt
- 11.4 m USD
- Equity
- 29.6 m USD
- Total assets
- 53.4 m USD
- Debt / equity
- 0.64x
- Current ratio
- 1.86x
- ROE
- 4.1%
- ROA
- 2.4%
- FCF margin
- -18.0%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|
| Revenue | 20.8 m | 19.2 m | 19.8 m | 23.5 m | 20.7 m | SEC (XBRL)· 10 Feb 2026verified |
| Cost of revenue | 14.4 m | 13.0 m | 13.0 m | 14.0 m | 14.6 m | SEC (XBRL)· 10 Feb 2026verified |
| Gross profit | 6.4 m | 6.2 m | 6.8 m | 9.5 m | 6.0 m | SEC (XBRL)· 10 Feb 2026verified |
| Research & development | 1.6 m | 1.9 m | 1.5 m | 1.5 m | 1.6 m | SEC (XBRL)· 10 Feb 2026verified |
| Operating income | 2.6 m | 2.1 m | 2.9 m | 3.6 m | 608.2 k | SEC (XBRL)· 10 Feb 2026verified |
| Depreciation & amortisation | 346.6 k | 362.6 k | 225.9 k | 237.8 k | 243.4 k | SEC (XBRL)· 10 Feb 2026verified |
| EBITDA | 3.0 m ≈ | 2.5 m ≈ | 3.1 m ≈ | 3.9 m ≈ | 851.6 k ≈ | SEC (XBRL)· 10 Feb 2026derived |
| Pre-tax income | 2.9 m | 2.7 m | 3.2 m | 4.2 m | 1.6 m | SEC (XBRL)· 10 Feb 2026verified |
| Income tax | 248.6 k | 36.1 k | 343.7 k | 763.9 k | 214.6 k | SEC (XBRL)· 10 Feb 2026verified |
| Net income | 2.6 m | 2.7 m | 2.9 m | 3.7 m | 1.2 m | SEC (XBRL)· 10 Feb 2026verified |
| Diluted EPS | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | SEC (XBRL)· 10 Feb 2026verified |
| Weighted average diluted shares | 135.0 m | 135.0 m | 145.1 m | 156.5 m | 156.5 m | SEC (XBRL)· 10 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|
| Cash | 3.7 m | 4.8 m | 6.9 m | 8.1 m | 7.5 m | SEC (XBRL)· 10 Feb 2026verified |
| Receivables | — | 3.8 m | 3.3 m | 5.9 m | 5.8 m | SEC (XBRL)· 10 Feb 2026verified |
| Inventories | — | 6.7 m | 5.1 m | 5.2 m | 4.9 m | SEC (XBRL)· 10 Feb 2026verified |
| Current assets | — | 18.9 m | 31.1 m | 42.8 m | 44.1 m | SEC (XBRL)· 10 Feb 2026verified |
| Property, plant & equipment, net | — | 1.6 m | 1.5 m | 1.5 m | 7.9 m | SEC (XBRL)· 10 Feb 2026verified |
| Intangibles (excl. goodwill) | — | — | 154.4 k | 1.1 m | 1.1 m | SEC (XBRL)· 10 Feb 2026verified |
| Total assets | — | 20.9 m | 32.9 m | 45.8 m | 53.4 m | SEC (XBRL)· 10 Feb 2026verified |
| Accounts payable | — | 4.1 m | 3.4 m | 3.0 m | 3.3 m | SEC (XBRL)· 10 Feb 2026verified |
| Short-term debt | — | — | 4.1 m | 11.3 m | 18.8 m | SEC (XBRL)· 10 Feb 2026verified |
| Current liabilities | — | 5.7 m | 8.9 m | 17.2 m | 23.8 m | SEC (XBRL)· 10 Feb 2026verified |
| Total liabilities | — | 5.7 m | 8.9 m | 17.2 m | 23.8 m | SEC (XBRL)· 10 Feb 2026verified |
| Equity | 14.0 m | 15.2 m | 24.0 m | 28.6 m | 29.6 m | SEC (XBRL)· 10 Feb 2026verified |
| Shares outstanding at year end | — | — | 155.9 m | 156.5 m | 156.5 m | SEC (XBRL)· 10 Feb 2026verified |
Cash flow · USD
| Line | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|
| Operating cash flow | 5.8 m | 1.6 m | 3.1 m | -1.2 m | 2.9 m | SEC (XBRL)· 10 Feb 2026verified |
| Capex | 42.9 k | 40.2 k | 113.9 k | 144.9 k | 6.6 m | SEC (XBRL)· 10 Feb 2026verified |
| Free cash flow | 5.8 m ≈ | 1.5 m ≈ | 3.0 m ≈ | -1.4 m ≈ | -3.7 m ≈ | SEC (XBRL)· 10 Feb 2026derived |
| Investing cash flow | -1.1 m | -120.9 k | -7.7 m | -9.5 m | -10.8 m | SEC (XBRL)· 10 Feb 2026verified |
| Financing cash flow | -2.9 m | 121.9 k | 6.9 m | 11.7 m | 7.4 m | SEC (XBRL)· 10 Feb 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
Score: 16 / 100
A scoring methodology on indicators and valuation, not investment advice.
score < 40
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 483.7 m USD
Key indicators
Coverage and freshness
The data is older than the freshness threshold.
Score by group
- Balance sheet25
- Growth11
- Valuation0
- Quality34
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 0.00 – 0.45 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · input data missing
- Peers: EV/EBITDA0.00 – 0.05 (Mid 0.01)7 companies used · median multiple 16.0x · quartiles 14.0x – 23.0xCDRE, ENOV, EW, MSA, SMTI, STE, ZBH
- Peers: P/E0.24 – 0.45 (Mid 0.30)9 companies used · median multiple 30.0x · quartiles 24.0x – 45.3xALGN, APT, CDRE, EW, ISRG, MSA, SNN, STE, ZBH
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Unattractive profile · Score 16/100
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | 1.4% | 36 (vs peers) | 13% |
| Net margin · Quality | 5.8% | 64 (vs peers) | 8% |
| FCF conversion · Quality | -312.8% | 0 (on a fixed band) | 8% |
| Revenue CAGR 3Y · Growth | 2.5% | 21 (on a fixed band) | 10% |
| EPS CAGR 3Y · Growth | -20.6% | 0 (on a fixed band) | 10% |
| Net debt / EBITDA · Balance sheet | 13.4x | 0 (vs peers) | 13% |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 1.9x | 88 (on a fixed band) | 5% |
| P/E (TTM) · Valuation | 309.0x | 0 (vs peers) | 13% |
| EV/EBITDA · Valuation | 581.4x | 0 (vs peers) | 13% |
| FCF yield · Valuation | -0.8% | 0 (on a fixed band) | 10% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet25/100 · 2/3 factors with a value
- Growth11/100 · 2/2 factors with a value
- Quality34/100 · 3/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation0/100 · 3/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
Jin Medical International Ltd. (ZJYL). Latest full fiscal year: 2025; data up to 2025-09-30.
Figures computed from the financial statements: revenue 20.7 m USD in 2025; YoY growth -12.0%; net margin 5.8%; ROE 4.1%; net debt/EBITDA 13.4x.
The estimated value range is 0.12–0.25 USD per share (median of 2 methods, agreement: low); assumptions are illustrative. Against the central value of 0.16 USD, the price of 3.09 USD leaves a potential of -94.9% (value / price − 1) and a margin of safety of -1,864.9% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
olivLaw score 16/100, methodological classification: unattractive profile (score, margin of safety and method agreement together; not a judgement of the right price). Groups assessed only in part: returns. Not investment advice.
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 1.9x
What contradicts it
- FCF conversion: -312.8%
- Revenue CAGR 3Y: 2.5%
- EPS CAGR 3Y: -20.6%
- Net debt / EBITDA: 13.4x
- P/E (TTM): 309.0x
- EV/EBITDA: 581.4x
- FCF yield: -0.8%
- The price is above the estimated value range
- The valuation methods diverge
Not assessed (insufficient data or a ratio without meaning): Interest coverage, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Orthopedic, Prosthetic & Surgical Appliances & Supplies (SIC 3842) · same industry (4-digit SIC) · compared with 23 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| ISRGIntuitive Surgical, Inc. | 167.1 bn | 58.3 | 18.0% | 25.5% | +20.5% | −16% / +55% |
| EWEdwards Lifesciences Corporation | 57.1 bn | 56.2 | 9.7% | 15.3% | +11.5% | +15% / +47% |
| SNNSmith & Nephew plc | 28.5 bn | 45.3 | 11.8% | 10.1% | +6.1% | −2% / +25% |
| STESTERIS plc | 24.2 bn | 30.0 | 11.4% | 13.3% | +8.7% | −7% / +23% |
| ZBHZimmer Biomet Holdings, Inc. | 20.8 bn | 27.9 | 6.0% | 9.0% | +7.2% | +13% / −5% |
| ALGNAlign Technology, Inc. | 11.6 bn | 24.0 | 11.9% | 11.8% | +0.9% | +12% / −23% |
| MSAMsa Safety Inc | 6.8 bn | 22.8 | 22.1% | 15.0% | +3.7% | +10% / +2% |
| ESTAEstablishment Labs Holdings Inc. | 2.0 bn | — | -175.3% | -15.8% | +27.1% | −3% / +161% |
| ENOVEnovis Corp | 1.4 bn | — | -54.3% | -48.0% | +6.7% | −19% / −51% |
| CDRECadre Holdings, Inc. | 1.3 bn | 33.8 | 11.6% | 5.6% | +7.5% | −28% / −4% |
| AVRAnteris Technologies Global Corp. | 596.4 m | — | -75.1% | -4,619.3% | −29.2% | +49% / unavailable |
| COCHEnvoy Medical, Inc. | 549.6 m | — | — | -11,304.8% | +7.1% | +749% / +216% |
| ZJYLJin Medical International Ltd. | 483.7 m | 309.0 | 4.1% | 5.8% | −12.0% | −34% / −66% |
| SMTISanara Medtech Inc. | 297.0 m | — | -147.7% | -29.2% | +19.0% | +55% / −0% |
| INGNInogen, Inc. | 191.6 m | — | -13.1% | -6.9% | +3.9% | +2% / +24% |
| LAKELakeland Industries, Inc. | 88.7 m | — | -19.6% | -14.0% | +15.2% | −41% / −39% |
| NTRBNutriband Inc. | 73.9 m | — | -100.7% | -430.4% | −4.8% | +23% / +140% |
| APTAlpha Pro Tech, Ltd. | 58.6 m | 14.1 | 6.6% | 6.8% | +2.3% | +25% / +17% |
| CLGNCollPlant Biotechnologies Ltd | 54.2 m | — | -117.6% | -484.6% | +360.4% | −81% / −92% |
| MYOMyomo, Inc. | 51.5 m | — | -123.8% | -33.5% | +25.7% | +46% / −58% |
| MLSSMilestone Scientific Inc. | 29.2 m | — | -121.7% | -44.0% | +4.0% | +6% / −61% |
| LFWDLifeward Ltd. | 17.2 m | — | -225.6% | -141.3% | −14.1% | −13% / −90% |
| CUPRCuprina Holdings (Cayman) Limited | 14.1 m | — | -1,115.0% | -9,366.7% | +9.2% | −64% / unavailable |
| BBLGBone Biologics Corporation | 1.2 m | — | -47.5% | — | 0.0% | −77% / −98% |
1- and 3-year price returns: for ZJYL from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | 1.36 Total return -56% · Per year -56% | 2.41 Total return -22% · Per year -22% | 3.63 Total return 18% · Per year 18% |
| 3 years | 1.27 Total return -59% · Per year -26% | 2.53 Total return -18% · Per year -6% | 4.20 Total return 36% · Per year 11% |
| 5 years | 1.18 Total return -62% · Per year -17% | 2.66 Total return -14% · Per year -3% | 4.86 Total return 57% · Per year 9% |
- Exit P/E± 0.63
- Net margin± 0.44
- Annual revenue growth± 0.37
- Annual dilution± 0.04
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 10 Feb 2026; since then the company filed 6-K (30 Oct 2026), 6-K (24 Sept 2026), 6-K (08 Sept 2026), 6-K (04 Aug 2026), 6-K (20 Jul 2026), 6-K (15 Jul 2026).
In brief
Jin Medical International Ltd. designs and manufactures wheelchairs and living aids for people with disabilities, the elderly and patients in recovery, through the variable interest entity Changzhou Zhongjin in China. The company reported revenue of 20.7 million USD in fiscal 2025, and its legal structure and the 2026 share class reclassification are of interest to investors.
SWOT
Strengths
Weaknesses
Opportunities
Risks
- Dependence on one large customerhigh
A significant portion of revenue comes from one large customer without a long-term contract, and losing this customer could materially affect results 1.
- VIE structurehigh
Contractual arrangements do not give the same control as share ownership, and Chinese authorities could find the structure non-compliant, which could reduce the value of the shares 1.
- Supplier dependencemedium
Raw materials come from a limited number of suppliers, and a disruption in supply could interrupt production and sales 1.
- Product liabilitymedium
Products carry inherent exposure to liability for personal injury claims, which could generate significant costs 1.
- Financing needsmedium
The company has limited sources of working capital and could need substantial additional financing to expand 1.
Investment thesis
What would need to be true (bull case)
- If sales of living aids and new categories keep growing, the company could diversify its business and support margins over the longer term 1.
- The dealer network and more than two decades of manufacturing experience could sustain the company's position in existing markets 1.
- If the share reclassification and capital structure changes are completed successfully, the company could gain more financial flexibility 1.
What would break the thesis
- Dependence on wheelchairs and on one major customer could seriously affect revenue if either source declines 1.
- Chinese authorities could challenge the VIE structure, which could make the shares hard to value and realise 1.
- Raw material cost pressure and rising selling expenses could reduce profitability if prices cannot be passed on to customers 1.
What to watch
- Completion of the share reclassification and Nasdaq approval2026
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 10 Feb 2026; since then the company filed 6-K (30 Oct 2026), 6-K (24 Sept 2026), 6-K (08 Sept 2026), 6-K (04 Aug 2026), 6-K (20 Jul 2026), 6-K (15 Jul 2026).
The business
The business operates through Changzhou Zhongjin and its subsidiaries, which design and manufacture wheelchairs and living aids for people with disabilities, the elderly and people recovering from injury 1. Most products are sold to dealers in Japan and China, while a small number reach dealers in the United States, Canada, Australia, Korea, Israel and Singapore 1. The company distributes about 98% of its products through qualified dealers, making the dealer network central to revenue 1.
The legal structure is unusual: the company controls Changzhou Zhongjin through a series of contractual arrangements (VIE agreements) rather than equity ownership, and consolidates it for accounting purposes only 1. These agreements have not been tested in a court of law, and Chinese authorities could disallow the structure, which could materially change operations and the value of the shares 1.
In January 2026 shareholders approved a reclassification of ordinary shares into Class A and Class B shares with different voting rights, which will not take effect until Nasdaq approval is obtained 1. The shares have traded on the Nasdaq Capital Market under the symbol ZJYL since March 2023 1.
Segments
Wheelchairs and components
The core segment accounted for about 87.5% of revenue in fiscal 2025 and consists almost entirely of manual wheelchairs across more than thirty models, while electric wheelchairs remain a small share of revenue 1.
Living aids
Oxygen concentrators and bathing machines accounted for about 11.6% of revenue in fiscal 2025, up from earlier years, showing gradual diversification 1.
New products
Oxygen chambers, beauty instruments and nano products were introduced in fiscal 2024, and the company notes that expansion into new categories brings new challenges and risks 1.
Market context
The company depends on demand from Japan and China but also sells in other regions, so results are exposed to trade and economic policies in several countries 1.
Trends
- Diversification into living aidstailwind
The share of living aids and new categories is growing gradually, which could reduce dependence on wheelchairs and could support margins if new products carry higher prices 1.
- Raw material cost pressureheadwind
Aluminium, steel and plastics have seen unforeseen price volatility, and the company buys up to three months in advance without fixed-price contracts, which could affect gross margin 1.
- Rising selling expensesmixed
Selling expenses rose from a small share of revenue in fiscal 2023 and are expected to keep increasing, while general and administrative expenses fell in fiscal 2025 1. The effect on profitability depends on whether sales growth can be sustained 1.
- Medical device and data regulationheadwind
Wheelchairs and living aids are classified as medical devices, and new Chinese rules on data and overseas listings could impose additional compliance requirements 1.
Competitive position
The company operates in highly competitive markets where larger competitors with greater scale and resources could compete more effectively, potentially reducing market share and revenue 1. The risk is heightened by dependence on one large customer without a long-term supply agreement 1.
The advantages described include more than two decades of wheelchair manufacturing experience, the ability to launch new products at higher prices, and established dealer relationships 1. The sources do not name specific competitors, so direct comparison remains limited 1.
- Larger-scale competitors
The source refers generally to competitors with greater scale and resources without naming them, so their identity cannot be confirmed from the document 1.
- Manual wheelchair makers with broad model ranges
The manual wheelchair market spans many price points, and competitors may offer wider ranges, described only generally in the source 1.
- Living aids suppliers
Competition in products such as oxygen concentrators and bathing machines is not detailed, though the segment is cited as a growth area 1.
- Component and raw material suppliers
The company relies on a limited number of raw material suppliers, and losing one could disrupt production 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report (foreign issuer)30 Oct 2026
- Current report (foreign issuer)24 Sept 2026
- Current report (foreign issuer)08 Sept 2026
- Current report (foreign issuer)04 Aug 2026
- Current report (foreign issuer)20 Jul 2026
- Current report (foreign issuer)15 Jul 2026
- Current report (foreign issuer)29 Jun 2026
- Current report (foreign issuer)04 Jun 2026
- Current report (foreign issuer)07 Apr 2026
- Current report (foreign issuer)17 Mar 2026
Sources
- [1] Form 20-F, fiscal year ended 2025-09-30 · SEC / Jin Medical International Ltd. · 10 Feb 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.